Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062478 · ClinicalTrials.gov registry record · Phase 2
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
A Phase 2 study, sponsored by BioNumerik Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00062478 is a Phase 2 study that has completed, run by BioNumerik Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT00062478, a Phase 2 study, has completed, sponsored by BioNumerik Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.
Interventions
- DRUG Karenitecin (BNP1350)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062478
The ClinicalTrials.gov registry entry for NCT00062478 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioNumerik Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Karenitecin (BNP1350) is the first listed.
NCT00062478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062478 about?
NCT00062478 is a clinical study titled "Study of Karenitecin (BNP1350) in Patients With Brain Tumors". The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.
What is the current status of trial NCT00062478?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2001-10.
What interventions are being tested in trial NCT00062478?
The interventions under investigation include: Karenitecin (BNP1350) (DRUG).
Who is sponsoring clinical trial NCT00062478?
This trial is sponsored by BioNumerik Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.